Peptide News Digest

FDA Clears GLP-1 Suicide Concerns, Oral Wegovy Explosion, Foundayo Launches at $25/Month, Utah Peptide Indictment

Wed, 08 Apr 2026 00:00:00 GMT

Today's peptide news cycle is dominated by a major FDA safety finding, the explosive launch of oral GLP-1 pills, and a continuing media blitz questioning the safety of unregulated peptide therapies. The FDA concluded that GLP-1 medications carry no increased suicide risk, requesting removal of warning labels — a significant win for the drug class. Meanwhile, Novo Nordisk's oral Wegovy pill is drawing a wave of new patients three months into its launch, and Eli Lilly's Foundayo (orforglipron) hit the market at $25/month for insured patients. On the enforcement front, a Utah physician was indicted for importing misbranded peptides from China, and 5,000 units were seized at the border.

1. FDA Finds No Increased Suicide Risk With GLP-1 Medications, Requests Warning Label Removal

Based on analysis of 107,910 patients, the FDA concluded there is no increased suicide risk associated with GLP-1 medications and has requested removal of related warning labels.

Read source | regulatory

2. Novo Nordisk's Oral Wegovy Pill Launch Draws Explosive New Patient Wave

Three months into its launch, oral Wegovy has driven explosive prescription demand, largely attracting new patients who avoided injections. Early data suggest the pill is expanding the obesity market rather than cannibalizing injectable users.

Peptide News Digest

FDA Clears GLP-1 Suicide Concerns, Oral Wegovy Explosion, Foundayo Launches at $25/Month, Utah Peptide Indictment

1. FDA Finds No Increased Suicide Risk With GLP-1 Medications, Requests Warning Label Removal

2. Novo Nordisk's Oral Wegovy Pill Launch Draws Explosive New Patient Wave

3. Eli Lilly's Foundayo (Orforglipron) Launches at $25/Month for Insured Patients

4. Noom Acquires Compounding Pharmacy TMC to Expand Into Peptide Therapies

5. Utah Physician Indicted for Importing Misbranded Peptides From China; 5,000 Units Seized

6. GLP-1 Therapies Rewriting Rules of Metabolic Disease at APhA 2026

7. Repositioning GLP-1 Drugs for Neurologic Disease Including Alzheimer's and Parkinson's

8. Amazon Pharmacy Adds FDA-Approved Oral Wegovy Pill

9. UK MHRA Probes Peptide Clinics Over Unlawful BPC-157 and MOTS-C Health Claims

10. FDA Warning Letters Target Marketers of Unapproved Weight Loss Drugs

GLP-1 Pricing Deal, Retatrutide Phase 3, Peptide Safety Investigations

1. The New Yorker Investigates the Gray-Market Peptide Injection Craze

2. Eli Lilly's Retatrutide Hits All Endpoints in Phase 3 Type 2 Diabetes Trial

3. Administration Announces Landmark GLP-1 Pricing Deal at $245/Month

4. A Third of Tested Peptide Products Fail Quality Checks, Guardian Investigation Finds

5. Retatrutide Users Report 'Emotional Flattening' and Falling Out of Love

6. FDA Had Already Warned Telehealth Startup MEDVi Over Misbranded GLP-1 Drugs

7. Foundayo vs. Oral Wegovy: Head-to-Head Oral GLP-1 Rivalry Heats Up

8. UK MHRA Launches Investigation into Peptide Clinics Making Medicinal Claims

9. Goldman Sachs: GLP-1 Drugs Could Add 1%+ to GDP, Reshape Food Industry

10. Syneron Bio Raises $150M for Macrocyclic Peptide Drug Development

Pinnacle Medicines $89M for Oral Peptides, Cagrilintide Phase 3 Monotherapy Results, Higher-Dose Wegovy 21% Weight Loss

1. Pinnacle Medicines Raises $89M for Oral Peptides Matching Injectable Biologics

2. Cagrilintide Demonstrates Promising Phase 3 Results as Obesity Monotherapy

3. STEP UP Trial: Higher-Dose Wegovy 7.2 mg Achieves 21% Mean Weight Loss

4. CagriSema Highlighted as Breakthrough Drug Set for Blockbuster Status by 2030

5. GQ: Why Fitness Bros Are Buzzing About Retatrutide

6. CBC Radio: Injectable Peptides Called 'A Giant Scam' by Scientists

7. Comprehensive Review of Incretins: From Semaglutide to Orforglipron and Retatrutide

8. Former FDA Officials Contest RFK Jr.'s Peptide Ban Misrepresentations

9. Novo Nordisk Implements Strategic Pricing and Volume Growth Measures

10. WeightWatchers Med+ Now Offering Oral Wegovy Pill at $149/Month

MHRA Peptide Clinic Probe, GLP-1 Price War, Orforglipron Approval

1. UK MHRA Launches Investigation Into Peptide Clinics Over Health Claims

2. GoodRx to Match Novo Nordisk Price for Oral Semaglutide

3. FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Takedown

4. India Tightens Watch on GLP-1 Drugs Amid Safety and Misuse Concerns

5. The Peptide Market Hits $50B — But Safety Questions Loom

6. FDA Approves Eli Lilly Oral GLP-1 Foundayo — Rivalry With Oral Wegovy Begins

7. Guardian Explainer: What Are Peptides and Is There Evidence Behind the Hype?

8. Beyond Weight Loss: GLP-1 Drugs Target Heart Failure, Kidney Disease, and Addiction

9. Oral Wegovy Pill Expands Access to GLP-1 Therapy for Chronic Weight Management

10. FDA Approves Orforglipron: First GLP-1 Pill Without Food or Water Restrictions

RFK Jr. Peptide Ban Reversal, Retatrutide Phase 3 Results, Oral Semaglutide vs Orforglipron

1. RFK Jr. May Reverse FDA Peptide Ban — Former Officials Push Back

2. Retatrutide Hits Primary Endpoints in Phase 3 Type 2 Diabetes Trial

3. Indirect Analysis: Oral Semaglutide May Beat Orforglipron on Weight Loss

4. FDA FAERS Data Reveal Different Risk Profiles Across GLP-1 Drugs

5. STAT News: Physician Says Patient Prefers BPC-157 Over Statins

6. Rusfertide Receives FDA Priority Review for Polycythemia Vera

7. Foundayo vs Oral Wegovy: Head-to-Head Comparison Analysis

8. Peptide-Based Therapies Show Promise in Wound Care Pipeline

9. Next-Gen GLP-1 Drugs Set to Reshape Food and Beverage Industry

10. iRGD-PLGA Nanocomplex Targets Chemoresistant Colon Cancer

Foundayo FDA Approval, Retatrutide TRIUMPH-4 Results, Semaglutide Safety Signal, Health Tech Peptide Bets

1. Scientific American: How Eli Lilly's New GLP-1 Pill Foundayo Stacks Up Against Wegovy

2. Retatrutide Achieves 28.7% Weight Loss and Knee Pain Reduction in TRIUMPH-4 Phase 3 Trial

3. Study Links Semaglutide to Rare Skin Pain Condition

4. FDA Approves Foundayo Under National Priority Voucher Program in Record 50 Days

5. Eli Lilly's Oral Obesity Pill Foundayo Approved, Kicking Off Renewed Novo Nordisk Rivalry

6. NBC News: FDA Approves GLP-1 Weight Loss Pill Foundayo with Six Dose Tiers

7. Hims & Hers Stock Retreats as Peptide Market Optimism Fades on Regulatory Uncertainty

8. Endpoints News: The Peptide Fad Lures Noom, Hims & Hers and Health Tech Companies

9. Ubrogepant Shows Enhanced Efficacy When Given During Mild Migraine Pain Phase

10. Eli Lilly Surpasses $1 Trillion Market Cap with 60% U.S. Incretin Market Share

FDA Approves Orforglipron, GLP-1 Cardiovascular Benefits, India Regulatory Crackdown

1. FDA Approves Eli Lilly's Foundayo (Orforglipron) as First Small-Molecule GLP-1 Pill for Obesity

2. Johns Hopkins Study Shows GLP-1 Drugs Reduce CV and Kidney Risk in Type 1 Diabetes

3. India's CDSCO Tightens Oversight on GLP-1 Drugs, Warns Against Weight Loss Misuse

4. ATTAIN-MAINTAIN Trial Shows Orforglipron Maintains Weight Loss After Injectable Switch

5. APhA2026 Highlights GLP-1 Expansion into Kidney Disease and Sleep Apnea

6. Foundayo Approval Intensifies Oral GLP-1 Market Competition Against Novo Nordisk

7. HIMS Stock Gains as FDA Signals Lifting Peptide Compounding Restrictions

8. FDA Poised to Reverse 2023 Peptide Ban Following RFK Jr. Advocacy

9. TB-500 and BPC-157 Characterized as Distinct Informational Modulators in New Review

10. STAT News: FDA Peptide Compounding Shift and Iran Conflict Impact on Clinical Trials

FDA Peptide Ban Reversal, GLP-1 Telehealth Crackdown, Novo Nordisk India Price Cuts

1. FDA Expected to Lift Peptide Compounding Ban at RFK Jr.'s Urging